Methods for treating hypercholesterolemia
View Patent ↗Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
1. A modified oligomeric compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleobase sequence of the oligonucleotide is at least 90% complementary to an equal-length portion of 3472-3562 of SEQ ID NO: 1, wherein the oligonucleotide has at least one modification.
2. The oligomeric compound of claim 1 , wherein the oligonucleotide consists of 20-25 linked nucleosides.
3. The oligomeric compound of claim 1 , wherein the oligonucleotide consists of 19-21 linked nucleosides.
4. The oligomeric compound of claim 3 , wherein the nucleobase sequence of the oligonucleotide is at least 95% complementary to an equal-length portion of 3472-3562 of SEQ ID NO: 1.
5. The oligomeric compound of claim 3 , wherein the nucleobase sequence of the oligonucleotide is fully complementary to an equal-length portion of 3472-3562 of SEQ ID NO: 1.
6. The oligomeric compound of claim 1 , wherein the oligonucleotide comprises a modified nucleobase.
7. A composition comprising the oligomeric compound of any of claims 1 - 5 or 6 , or a salt thereof and a pharmaceutically acceptable carrier or diluent.
8. A method comprising administering to a human with hypercholesterolemia, polygenic hypercholesterolemia, mixed dyslipidemia, coronary heart disease, acute coronary syndrome, early onset coronary heart disease, type II diabetes, type II diabetes with dyslipidemia, hepatic steatosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hypertriglyceridemia, hyperfattyacidemia, hyperlipidemia, metabolic syndrome, atherosclerosis, elevated ApoB, elevated cholesterol, elevated LDL-cholesterol, elevated VLDL-cholesterol, or elevated non-HDL cholesterol, a therapeutically effective amount of a composition comprising an oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleobase sequence of the oligonucleotide is at least 90% complementary to an equal-length portion of 3472-3562 of SEQ ID NO: 1.
9. The method of claim 8 , wherein the elevated LDL-cholesterol level is above a target level of at least about 100 mg/dL, 130 mg/dL, 160 mg/dL, or 190 mg/dL.
10. The method of claim 8 , wherein administering the composition results in an LDL-cholesterol level below a target level of at least about 190 mg/dL, 160 mg/dL, 130 mg/dL, 100 mg/dL, 70 mg/dL, or 50 mg/dL.
11. The method of claim 8 , wherein administering said composition results in a reduction of ApoB, LDL-cholesterol, VLDL-cholesterol, Lp(a), small LDL-particle, small VLDL-particle, non-HDL-cholesterol, liver triglyceride level, serum triglycerides, serum phospholipids, or any combination thereof.
12. The method of claim 11 , wherein at least one of the ApoB reduction, the LDL-cholesterol reduction, the, VLDL-cholesterol reduction, the Lp(a) reduction, the small LDL-particle reduction, the small VLDL-particle reduction, the non-HDL-cholesterol reduction, the liver triglyceride level reduction, the serum triglycerides reduction, or serum phospholipids reduction is at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
13. The oligomeric compound of claim 3 , wherein the oligonucleotide consists of 19 linked nucleosides.